e-Therapeutics plc - Notice of AGM and Annual Report
Notice of Annual General Meeting and Annual Report
The 2020 AGM will take place at
Shareholders who wish to register their votes on the resolutions to be put to the AGM without attending in person should do so by completing and signing the proxy form that accompanied the 2020 AGM Notice (or appoint a proxy electronically if their shares are held in CREST) in accordance with the instructions printed on the proxy form. Please return your forms as soon as possible and in any event prior to
If you do not have a proxy form and believe that you should have one, or if you have any additional queries on voting, please contact our registrar at
For more information, please contact:
Tel: +44 (0)1993 883 125
Tel: +44 (0) 207 260 1000
Tel: +44 (0) 203 727 1000
Email: [email protected]
e-therapeutics is an
We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.
The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").
We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.
We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.
This information is provided by RNS, the news service of the
Quick facts: e-Therapeutics PLC
Market Cap: £63.68 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE